SEAQUAMATSoutheast Asia Quinine Artesunate Malarial Trial
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
The other issue of importance is that because the patients in these studies were not necessarily in an intensive care unit (ICU) (SEAQUAMAT does not state where they were managed but, in AQUAMAT, patients were managed in the ward), [4,5] the results cannot be translated to a setting where modern ICU facilities are available.
This again makes me wonder why there were no obvious differences in secondary outcomes in the SEAQUAMAT and AQUAMAT studies [4,5] as described above.
The physician noted that the landmark South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) recently showed in 1,461 randomized patients with severe falciparum malaria a compelling 35% reduction in the relative risk of death with artesunate (Lancet 2005;366:717-25).
[2,5] The South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) was an open-label, randomised trial of 1 461 patients with severe malaria.